Aleris Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 27-10-2024
- Paid Up Capital ₹ 0.50 M
as on 27-10-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Net Worth 0.48%
(FY 2023)
- Total Assets 2.86%
(FY 2023)
About Aleris Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rubi Mukhopadhyay, Biswajit Pan, and Anand Parmanandka serve as directors at the Company.
- CIN/LLPIN
U24304WB2021PLC245141
- Company No.
245141
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 May 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aleris Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rubi Mukhopadhyay  | Director | 13-May-2021 | Current |
| Biswajit Pan | Director | 13-May-2021 | Current |
| Anand Parmanandka | Director | 13-May-2021 | Current |
Financial Performance of Aleris Pharmaceuticals.
Aleris Pharmaceuticals Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 0.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aleris Pharmaceuticals?
In 2022, Aleris Pharmaceuticals had a promoter holding of 99.99% and a public holding of 0.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Alventa Pharma LimitedActive 8 years 2 monthsRubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Elder Laboratories LimitedActive 3 years 7 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Nicholas Pharma India LimitedActive 3 years 9 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
- Allenburys Pharma LimitedActive 4 years 2 months
Rubi Mukhopadhyay, Biswajit Pan and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aleris Pharmaceuticals?
Aleris Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aleris Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aleris Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
